Lee et al. showed that the phosphorylation of Y397 and Y576 on the focal adhesion kinase (FAK) is associated with resistance to docetaxel in a metastatic prostate cancer cell line, and that a combination therapy with FAK tyrosine kinase inhibitor can overcome the resistance [273]. Here, PTK2 is linked to metastatic prostate carcinoma.